Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amphora Discovery Corporation has entered into a multi-year research partnership with Ortho-McNeil Pharmaceutical, to discover and develop new treatments for inflammatory disease, including some cardio and respiratory indications.
Subscribe to our email newsletter
Under the terms of the agreement, Ortho-McNeil Pharmaceutical will license several lead series of compounds identified by Amphora that are focused on a widely recognized inflammation target for which a successful therapy has not yet been identified.
North Carolina-based Amphora will grant Ortho-McNeil Pharmaceutical exclusive rights to the existing compounds as well as new compounds discovered during the collaboration. Ortho-McNeil’ Pharmaceutical’s affiliate, Johnson & Johnson Pharmaceutical R&D, will further develop the licensed compounds and provide research support to Amphora.
Financial terms of the agreement were not disclosed, but include research support payments, an up-front licensing fee and the possibility of milestone payments and royalties for compounds developed under the collaboration.